Influenza Articles
A new vaccine may help speed up the process of making antibodies against SARS-CoV-2 by using preexisting immunity to a separate virus (the influenza virus).
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
A study by researchers at Georgia State University's Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
Researchers in a study funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health have developed an influenza (flu) vaccine administered through the nose that has been constructed with nanoparticles and offers stronger protection.
Two studies show the influenza (flu) and pneumonia vaccines lessen the risk of developing Alzheimer’s disease (AD) in the future.
A recent experiment found offering healthcare providers financial incentives and creating competition by informing clinics how their performance ranked relative to others were effective in increasing influenza (flu) vaccine rates among patients.
A new study shows cardiovascular outcomes may improve in individuals with hypertension if they receive the influenza (flu) vaccine during the flu season.
Researchers at the University of Rochester Medical Center in New York City have developed a new type of skin patch that could replace needles as a method to deliver the influenza (flu) vaccine.
A new study that looked at how the influenza (flu) virus escapes antibodies found the site of the escape mutation varies among most individuals’ sera.
The National Institutes of Health (NIH) is conducting an early-stage clinical trial to evaluate the safety and efficacy of two licensed seasonal influenza vaccines administered with or without novel adjuvants.